ACCEL Lite: AHA Late-Breaker ORBITA-2: Percutaneous Coronary Intervention for Stable Angina: A Randomized, Placebo-Controlled Trial
ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research - Un podcast de American College of Cardiology - Les mardis
Catégories:
ORBITA-2 was designed to test whether stents reduce angina more than a placebo procedure in patients with single or multivessel disease on little or no antianginal medication at 12 weeks of follow up. In this interview, Christopher Rajkumar, MD, Rasha Al-Lamee, MD, and William E. Boden MD, FACC, discuss AHA Late-Breaker: Percutaneous Coronary Intervention for Stable Angina (ORBITA-2): A Randomized, Placebo-Controlled Trial. Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL
